tapebrief
ALGN · Q3 2025
ALGN · Q1 2026
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

ALGN · Q4 2025 Earnings

Align Technology

Reported February 4, 2026

30-second summary

30-second take: Q4 revenue of $1.048B (+5.3% YoY) cleared the high end of the $1,025–1,045M guide on Clear Aligner volume of 676.9K (+7.7% YoY) — the cleanest volume print in over a year — while non-GAAP operating margin landed at 26.1%, matching guide. Management broke its three-quarter silence on 2026 with a +3–4% revenue growth guide and ~400bp GAAP operating margin expansion to "slightly below 18.0%", explicitly excluding any China VBP impact and accepting near-term direct-fab margin dilution. The volume reacceleration sustains, but the FY26 top-line decel from the +7.7% Q4 exit rate to +3–4% says management does not underwrite this run-rate as the new baseline.

Headline numbers

EPS

Q4 FY2025

$3.29

Revenue

Q4 FY2025

$1.05B

+5.3% YoY

Gross margin

Q4 FY2025

65.3%

Operating margin

Q4 FY2025

14.8%

Key financials

Q4 FY2025
MetricQ4 FY2025YoYQ3 FY2025QoQ
Revenue$1.05B+5.3%$1.00B+5.2%
EPS$3.29—$2.61+26.1%
Gross margin65.3%—64.2%+110bps
Operating margin14.8%—9.7%+510bps

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueQ4 FY2025$1,025M to $1,045M$1,047.6M+$2.6M to +$22.6M above guideBeat
GAAP Gross MarginQ4 FY202565.5% to 66.0%65.3%-0.2pt to -0.7pt below guidance, within reasonable toleranceMet
Non-GAAP Gross MarginQ4 FY2025approximately 71.0%72.0%+1.0pt above guideMet
GAAP Operating MarginQ4 FY202515.3% to 15.8%14.8%-0.5pt to -1.0pt below guidance rangeMet
Non-GAAP Operating MarginQ4 FY2025approximately 26.0%26.1%+0.1pt above guideBeat
Non-GAAP Operating MarginFY 2025slightly above 22.5%22.6%+0.1pt above guidanceMet

New guidance

MetricPeriodGuideYoY
Revenue GrowthFY 2026up 3% to 4% year-over-year—
Clear Aligner Volume GrowthFY 2026up mid-single digits year-over-year—
GAAP Operating MarginFY 2026slightly below 18.0%, approximately 400 basis points improvement over 2025—
Non-GAAP Operating MarginFY 2026approximately 23.7%, 100 basis points improvement year-over-year—

Reaffirmed unchanged this quarter: GAAP Operating Margin (13.5%)

Segment KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
Clear Aligner Revenue$0.838B+5.5%
Imaging Systems and CAD/CAM Services Revenue$0.209B+4.2%

Other KPIs

Q4 FY2025
SegmentQ4 FY2025
Clear Aligner Cases Shipped676.9 thousand
Clear Aligner Volume YoY Growth7.7%
Clear Aligner Volume Sequential Growth4.5%
Invisalign Trained Doctors Submitters87.7 thousand
Active iTero Scanner Units121 thousand
Clear Aligner Revenue Per Case$1,240
Non-GAAP Operating Margin26.1%
Non-GAAP Gross Margin72.0%

Management tone

Narrative arc: Q2 Restructuring narrative replaces growth narrative → Q3 Volume reaccelerates but North America retail still broken → Q4 Volume sustains, FY26 anchored on margin not growth.

Three quarters ago management reframed the business as a cost-out story after Clear Aligner volume printed +0.3% YoY; two quarters ago volume reaccelerated to +4.9% but management refused to give 2026 top-line color; this quarter volume hit +7.7% and management finally anchored 2026 at +3–4% revenue growth. The verbatim posture — "While the macro environment remains dynamic, we are cautiously optimistic with a strong innovation roadmap, disciplined operational execution... we believe we are well positioned to deliver growth and value in 2026 and beyond" — frames execution as the lever rather than market tailwinds. The FY26 top-line guide is meaningfully below the Q4 exit run-rate of +5.3% revenue and +7.7% volume, which says management treats the back-half-2025 reacceleration as partly cyclical, not durable.

The North America diagnosis has tightened further. Q2 framed weakness as patient demand plus doctor behavior plus financing across multiple geographies; Q3 isolated it to the U.S. retail channel; Q4 reframes the channel as the solution — "Our top 10 DSOs in the Americas grew double digits year over year... DSOs continue to drive expansion in both Invisalign case volume and iTero scanner penetration." DSOs now represent a meaningful and growing share of volume per management commentary, and the story has shifted from "retail orthodontist is broken" to "DSO penetration is the offset." That is a strategic concession dressed as channel acceleration.

China VBP, the most evasive topic of Q3, has been explicitly removed from the 2026 forecast. Management said early phases are expected within the public hospital system before broader expansion, with "timing and scope remain fluid," and noted over 85% of Align's China business is in the private sector. Removing a known uncertainty variable from guidance — rather than scenario-bracketing it — is a defensive choice that protects the FY26 print but leaves a known unmitigated risk hanging over the year. If VBP implementation lands mid-2026, the guide breaks.

Direct fabrication has shifted from future investment to active near-term margin headwind. Management confirmed Invisalign First direct 3D-printed retainers reach limited market release in 2026, with more complex products in 2027, and explicitly stated that "early production has some dilutive margin impact until scale" — contemplated within the ~100bp non-GAAP operating margin improvement guide. That is a meaningful tell: the ~100bp non-GAAP expansion is being achieved despite a margin headwind, which implies the underlying cost-out from H2 2025 restructuring is doing more work than the headline number suggests.

Recurring themes management leaned on this quarter:

DSO penetration and double-digit to triple-digit growth as primary growth engineNorth America stabilization through improved retail conversion and DSO expansionTeen/kids segment acceleration (Invisalign First, Pallet Expander, MAOB) as long-term opportunityInternational expansion (Latin America, EMEA, APAC) driving volume growthDirect fabrication transition and margin accretion pathwayAI-enabled tools and digital workflow integration (ClinCheck Live, iTero Lumina) as competitive advantage

Risks management surfaced:

China VBP (volume-based procurement) pricing pressure and timing uncertaintyMacroeconomic headwinds affecting North American consumer discretionary spendingForeign exchange volatility impacting ASP and marginsDirect fabrication margin dilution in 2026 before scale benefits arriveCompetitive pricing responses and market share dynamics

Answers to last quarter's watch list

Q4 revenue vs $1,035M midpoint and FY volume settling in mid-single digits. Revenue printed $1,047.6M, $2.6M above the high end of $1,025–1,045M and $12.6M above midpoint. Clear Aligner volume grew +7.7% YoY for Q4 and FY25 volume grew +4.7%, in the mid-single-digit range as guided. Status: Resolved positively
Q4 GAAP operating margin recovery to 15.3–15.8%. GAAP operating margin came in at 14.8%, 50bps below the low end. Non-GAAP at 26.1% met guide. The miss is modest but it means the restructuring drag was not fully cleared by Q4 — and Q1'26 GAAP margin is guided to 12.4–12.8%, which embeds further sequential pressure before the FY26 ramp to slightly below 18.0%. Status: Resolved negatively
Systems & Services deferred revenue trajectory. Systems & Services deferred revenue was flat sequentially and decreased $24.6M (-11.2%) year-over-year, per the CFO, attributed in part to shorter-duration service contracts on initial scanner purchases. Combined with S&S revenue of $209.4M (+4.2% YoY), the read on doctor capex appetite is mixed: scanner volumes are growing but deferred-revenue build is not. Status: Resolved negatively
First 2026 top-line color. Management anchored FY26 revenue growth at +3–4% YoY — the first explicit 2026 top-line guide after declining on the Q3 call. The number itself sits below the Q4 exit rate, signaling management does not underwrite recent reacceleration as durable. Status: Resolved negatively (the disclosure happened, but the magnitude undercuts the bull case)
North American retail metrics. No specific U.S. retail volume disclosure, but management quantified DSO strength: top 10 Americas DSOs grew double digits YoY and North America DSO performance delivered double-digit YoY growth led by adults. The reframe from "retail problem" to "DSO solution" is the answer — retail itself was characterized as "stability" rather than improvement, which is itself a tell. Status: Continue monitoring
China VBP scope and provincial implementation. Management explicitly excluded any VBP impact from FY26 guidance and said early phases are expected within the public hospital system before broader expansion, with "timing and scope remain fluid." The risk is acknowledged and bracketed out of the model rather than quantified. Status: Not resolved

What to watch into next quarter

Q1'26 revenue vs $1,020M midpoint and Clear Aligner volume YoY. Guide implies +3–5% YoY revenue; a print at the high end with volume holding mid-single digits would validate the Q4 trend. A miss below midpoint puts the FY26 +3–4% guide at immediate risk in the first quarter of the year.

GAAP operating margin trajectory toward FY26 slightly below 18.0%. Q1'26 GAAP guide of 12.4–12.8% is a sequential drop from Q4's 14.8%; achieving "slightly below 18.0%" for the full year requires meaningful H2'26 expansion. Watch whether Q2'26 commentary frames the ~400bp lift as front-loaded restructuring savings or back-half operating leverage.

China VBP implementation news flow. Management's guidance excludes any VBP impact. Any provincial implementation announcement in H1'26 — particularly anything affecting public hospital pricing — would force a guide revision.

Direct fabrication ramp progress and margin commentary. Invisalign First direct 3D-printed retainers reach limited market release in 2026. Watch for any quantification of unit ramp, factory utilization, or the magnitude of the dilution embedded in the ~100bp non-GAAP margin guide.

DSO mix progression. This is now the strategic growth engine in management's framing, with top 10 Americas DSOs growing double digits and top 10 EMEA DSOs growing triple digits. Watch for any quantified DSO volume-share update — continued double-digit growth from this cohort against flat-to-down retail would confirm the structural channel shift.

Sources

  1. Align Technology Q4 2025 earnings press release, February 4, 2026 — https://www.sec.gov/Archives/edgar/data/1097149/000109714926000006/algn-q425earningspressrele.htm
  2. Align Technology Q3 2025 earnings press release, October 29, 2025 — https://www.sec.gov/Archives/edgar/data/1097149/000109714925000075/algn-q325earningspressrele.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.